Image Source: AsiaOne
Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in EuropeGlobeNewswireJuly 13, 2020Angelini Pharma obtains exclusive development, manufacturing and commercialization rights to OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the European Union and other countries in the European Economic Area (Switzerland, Turkey and the United Kingdom) and RussiaOvid Therapeutics will receive an upfront payment of $20 million and additional payments of up to $212.5 million upon the achievement of development, manufacturing and sales milestones, in addition to double-digit royalties on net sales if successfully commercialized Angelini Pharma will execute the agreement through its new affiliate Angelini Pharma Rare Diseases AG Ovid to host conference call and webcast today at 8:15 a.m.
Source: AsiaOne